Quince Therapeutics (QNCX)

Executive Summary

Quince Therapeutics is a late-stage biotechnology company pioneering its proprietary AIDE (autologous red blood cell encapsulation) platform to enable chronic administration of drugs with known efficacy but limiting toxicity. The lead program, eDSP (erythrocyte-delivered dexamethasone sodium phosphate), targets Ataxia-Telangiectasia (A-T), a rare neurodegenerative disease. In late 2025, the company reported topline results from the pivotal Phase 3 NEAT trial evaluating eDSP in A-T. While the trial met its primary endpoint of reducing neurological deterioration, the magnitude of benefit was modest, and the safety profile was consistent with expectations. The stock reacted negatively as investors had hoped for a more robust effect. Following the data, management announced it is actively exploring strategic alternatives, including a potential sale, merger, or partnership, to maximize shareholder value. The company has a cash runway into late 2026, providing a buffer for negotiations. Quince also has an earlier-stage pipeline exploring eDSP in other rare diseases, but near-term value hinges on the strategic process and potential regulatory discussions. Given the mixed data and uncertain path forward, the conviction score is moderate.

Upcoming Catalysts (preview)

• Q3 2026Announcement of strategic alternative outcome (sale, merger, or partnership)60% success
• Q2 2026Publication of detailed Phase 3 NEAT trial results or presentation at a medical conference80% success
• Q4 2026Potential FDA meeting or regulatory guidance for eDSP in A-T30% success